

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H47540DEBA79EN.html>

Date: November 2022

Pages: 79

Price: US\$ 2,000.00 (Single User License)

ID: H47540DEBA79EN

Abstracts

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]

Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 4, 10, 3 and 1 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of

development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies

Involved in Therapeutics Development

ADARx Pharmaceuticals Inc

Astria Therapeutics Inc

Attune Pharmaceuticals

BioMarin Pharmaceutical Inc

Bioviz Technologies Pvt Ltd

Bridge Medicines LLC

CAMP4 Therapeutics Corp

CSL Ltd

Intellia Therapeutics Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Octapharma AG

Pharming Group NV

Pharvaris NV

Ractigen Therapeutics Inc

Spark Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Verseon Corp

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles

ADX-324 - Drug Profile

Product Description
Mechanism Of Action
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
BMN-331 - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
donidalorsen sodium - Drug Profile
Product Description
Mechanism Of Action
garadacimab - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
Haegarda - Drug Profile
Product Description
Mechanism Of Action
IONIS-PKCRx - Drug Profile
Product Description
Mechanism Of Action
KV-998052 - Drug Profile
Product Description
Mechanism Of Action
KV-998054 - Drug Profile

Product Description

Mechanism Of Action

KV-998086 - Drug Profile

Product Description

Mechanism Of Action

KVD-998083 - Drug Profile

Product Description

Mechanism Of Action

Ianadelumab - Drug Profile

Product Description

Mechanism Of Action

NTLA-2002 - Drug Profile

Product Description

Mechanism Of Action

Oligonucleotides to Activate SERPING1 for Hereditary Angioedema (HAE) - Drug Profile

Product Description

Mechanism Of Action

OTL-105 - Drug Profile

Product Description

Mechanism Of Action

PHVS-416 - Drug Profile

Product Description

Mechanism Of Action

PHVS-719 - Drug Profile

Product Description

Mechanism Of Action

RAG-12 - Drug Profile

Product Description

Mechanism Of Action

sebetralstat - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Factor XII for Hereditary Angioedema and Inflammation - Drug Profile

Product Description

Mechanism Of Action

STAR-0215 - Drug Profile

Product Description

Mechanism Of Action

VE-4062 - Drug Profile

Product Description

Mechanism Of Action

VE-4666 - Drug Profile

Product Description

Mechanism Of Action

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones

Featured News & Press Releases

Nov 21, 2022: Takeda receives prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO (lanadelumab)

Nov 14, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 ACAAI Annual Scientific Meeting

Nov 13, 2022: Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Nov 12, 2022: Intellia Therapeutics presents new interim data from first-in-human study of NTLA-2002 for the treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

Nov 07, 2022: Astria Therapeutics to present STAR-0215 modeling and simulation data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

Oct 31, 2022: KalVista Pharmaceuticals announces positive phase 1 data for orally disintegrating tablet formulation of sebetralstat for use in hereditary angioedema

Oct 19, 2022: KalVista Pharmaceuticals announces publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

Oct 07, 2022: KalVista Pharmaceuticals presents new patient-centric data at 2022 HAEi Global Leadership Workshop

Oct 05, 2022: U.S. Food and Drug Administration accepts Takeda's Supplemental Biologics License Application for use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older

Sep 30, 2022: Astria Therapeutics to host virtual R&D Day: update on STAR-0215 and its clinical development

Sep 16, 2022: Intellia Therapeutics announces positive interim clinical data for its second systemically delivered investigational CRISPR candidate, NTLA-2002 for the

treatment of hereditary angioedema (HAE)

Sep 16, 2022: Intellia Therapeutics to present interim clinical data from ongoing phase 1/2 study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 Bradykinin Symposium

Sep 16, 2022: Intellia Therapeutics announces upcoming investor event to present interim clinical data from ongoing first-in-human studies of NTLA-2002 on September 16, 2022

Sep 01, 2022: Intellia Therapeutics receives U.S. FDA orphan drug designation for NTLA-2002, an investigational CRISPR therapy for the treatment of Hereditary Angioedema

Aug 23, 2022: KalVista Pharmaceuticals announces initiation of KONFIDENT-S open label extension study for sebetralstat in hereditary angioedema

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ADARx Pharmaceuticals Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Astria Therapeutics Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Attune Pharmaceuticals, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioMarin Pharmaceutical Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bioviz Technologies Pvt Ltd, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bridge Medicines LLC, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CAMP4 Therapeutics Corp, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Intellia Therapeutics Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Octapharma AG, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by

Pharming Group NV, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharvaris NV, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ractigen Therapeutics Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Spark Therapeutics Inc, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022 (Contd..1)

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H47540DEBA79EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H47540DEBA79EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970